279 results on '"Santagostino E"'
Search Results
2. Polypharmacy in older adults with severe haemophilia
3. Ageing successfully with haemophilia: A multidisciplinary programme
4. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three‐year follow‐up of the AHEAD (Advate in HaEmophilia A outcome Database) study
5. Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A
6. First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A
7. European retrospective study of real-life haemophilia treatment
8. New findings on inhibitor development: from registries to clinical studies
9. Thrombin Generation Assay (TGA) for Testing of Haemostatic Effectiveness of Factor VIII (FVIII) Concentrates in Patients with Hemophilia A and Inhibitors: In Vitro Results from the Predictga Study: OR04
10. Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors
11. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients
12. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial
13. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: Non-interventional, observational study in patients with severe haemophilia A
14. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
15. Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?
16. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product
17. New predictive approaches for ITI treatment
18. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa
19. Inhibitors – genetic and environmental factors
20. Integrated postural analysis in children with haemophilia
21. Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity
22. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate
23. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics
24. Models for institutional and professional accreditation of haemophilia centres in Italy
25. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry
26. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance
27. Determinants of the response to DDAVP in mild hemophilia A patients: PO-TU-122
28. Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients: PO-WE-142
29. Successful Immune Tolerance Induction in Patients with Hemophilia A and Inhibitors Treated with a Plasma-Derived FVIII Product Containing von Willebrand Factor: A Large International, Multicentre, Retrospective Study: PO-WE-126
30. The role of the rs12979860 polymorphism of the interleukin-28b as a predictor of sustained virological response after antiviral therapy in patients with hemophilia and chronic hepatitis C: PO-MO-108
31. Source and purity of factor VIII products as risk factors for inhibitor development in previously untreated patients with severe hemophilia A: FP-WE-01.1-3
32. Predictors of success of immune tolerance induction in hemophilia A patients with high-responding inhibitors: A score from the Italian registry: FP-WE-04.2-2
33. The role of the rs12979860 polymorphism of the interleukin-28b as predictor of spontaneous clearance of HCV infection in patients with hemophilia: PO-MO-107
34. Pharmacoeconomic Evaluation with an Activated Prothrombin Complex Concentrate (APCC) in Patients with Hemophilia and Inhibitors (PRO FEIBA Study): PO-MO-052
35. Cost of immune tolerance induction in hemophilia A patients: Results from the ITER study: PO-MO-051
36. Bypassing therapy in patients with hemophilia and inhibitors: In vivo studies of thrombin generation capacity: PO-TU-079
37. Safety and pharmacokinetic results of a phase I/II clinical trial of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B (PROLONG-9FP): PO-WE-055
38. Results of a phase I international clinical trial of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in patients with hemophilia B (PROLONG-9FP): FP-MO-03.2-6
39. MUOVIAMOCI (Italian Musculoskeletal Global Project): PO-MO-017
40. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies
41. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrandʼs disease: a systematic review of prospective studies
42. Management of bleeding disorders: basic science
43. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) – an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A
44. When should prophylaxis therapy in inhibitor patients be considered?
45. Joint protection in haemophilia
46. Dental surgery in inherited bleeding disorders with minimal factor support: commentary
47. The need for speed in the management of haemophilia patients with inhibitors
48. F8 mRNA studies in haemophilia A patients with different splice site mutations
49. Clinical issues in inhibitors
50. Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.